ASH 2019 MM

Almost 90% of patients responded to infusions of the LCAR B38M, and the majority of complete responders became minimal residual disease–negative. Read More ›

Newly diagnosed patients receiving daratumumab/lenalidomide/dexamethasone achieved rapid and deep responses. Read More ›

Positron emission tomography combined with computed tomography (PET/CT)/minimal residual disease–negativity concordance could be a predictive surrogate for patient outcomes. Read More ›

For the first time, overall survival benefit of adding daratumumab to standard of care in newly diagnosed, transplant-ineligible multiple myeloma patients is confirmed. Read More ›

After induction with daratumumab and CyBorD, maintenance daratumumab improves depth of response and survival in newly diagnosed and relapsed multiple myeloma. Read More ›

Presented as a late-breaking abstract, CANDOR met its primary end point, showing that daratumumab/carfilzomib/dexamethasone significantly prolonged progression-free survival. Read More ›

Responses were achieved by more than 90% of patients receiving JNJ-4528, and all patients tested for minimal residual disease (MRD) status were MRD-negative. Read More ›

In an analysis of more than 10,000 relapsed/refractory patients treated in routine clinical practice with ixazomib/lenalidomide/dexamethasone, outcomes were as good as those reported in clinical trials. Read More ›

Final analysis of patient-reported outcomes from the phase 3 ELOQUENT-2 trial confirms elotuzumab has no negative impact on health-related quality of life. Read More ›

In patients with relapsed/refractory multiple myeloma, treatment with elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone shows encouraging responses, with manageable toxicity. Read More ›

Page 1 of 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: